Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: Implications for human disease

Annals of Surgery

Volumn 247, Issue 5, 2008, Pages 860-868

  Isenberg, Jeff S ^a   Romeo, Martin J ^a   Maxhimer, Justin B ^a,b   Smedley, Jeremy ^b   Frazier, William A ^c   Roberts, David D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE MORPHOLINO OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; CD47 ANTIGEN; CYCLIC GMP; MONOCLONAL ANTIBODY; NITRIC OXIDE; NITRIC OXIDE DONOR; THROMBOSPONDIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; GENE SILENCING; IMMUNOPHARMACOLOGY; ISCHEMIA; MINIPIG; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TISSUE FLAP; TISSUE PERFUSION; TISSUE REGENERATION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD47; GENE SILENCING; ISCHEMIA; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; SIGNAL TRANSDUCTION; SURGICAL FLAPS; SWINE; SWINE, MINIATURE; THROMBOSPONDIN 1; TISSUE CULTURE TECHNIQUES; TISSUE SURVIVAL;

EID: 42549122989     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31816c4006     Document Type: Article

References (49)

1. Ashcroft GS, Horan MA, Ferguson MW. The effects of ageing on cutaneous wound healing in mammals. J Anat. 1995;187(pt 1):1-26.
2. Ashcroft GS, Mills SJ, Ashworth JJ. Ageing and wound healing. Biogerontology. 2002;3:337-345.
3. Marin J. Age-related changes in vascular responses: a review. Mech Ageing Dev. 1995;79:71-114.
4. Reed MJ, Edelberg JM. Impaired angiogenesis in the aged. Sci Aging Knowledge Environ. 2004;2004:pe7.
5. Sigvant B, Wiberg-Hedman K, Bergqvist D, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 2007;45:1185-1191.
6. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol. 2002;53(4 pt 1):503-414.
7. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res. 1989;65:1-21.
8. Murad F. Cyclic GMP: synthesis, metabolism, and function. Introduction and some historical comments. Adv Pharmacol. 1994;26:1-5.
9. Cooke JP. NO and angiogenesis. Atheroscler Suppl. 2003;4:53-60.
10. Napoli C, de Nigris F, Williams-Ignarro S, et al. Nitric oxide and atherosclerosis: an update. Nitric Oxide. 2006;15:265-279.
11. Desjardins F, Balligand JL. Nitric oxide-dependent endothelial function and cardiovascular disease. Acta Clin Belg. 2006;61:326-334.
12. Isenberg JS, Ridnour LA, Perruccio EM, et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA. 2005;102:13141-13146.
13. Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res. 2006;71:785-793.
14. Isenberg JS, Hyodo F, Matsumoto K, et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood. 2007;109:1945-1952.
15. Isenberg JS, Ridnour LA, Dimitry J, et al. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem. 2006;281:26069-26080.
16. Isenberg JS, Romeo MJ, Abu-Asab M, et al. Increasing survival of ischemic tissue by targeting CD47. Circ Res. 2007;100:712-720.
17. Isenberg JS, Pappan LK, Romeo MJ, et al. Blockade of thrombospondin-1- CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg. 2008;247:180-190.
18. Isenberg JS, Hyodo F, Pappan LK, et al. Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol. 2007;27:2582-2588.
19. de Smet BJ, van der Zande J, van der Helm YJ, et al. The atherosclerotic Yucatan animal model to study the arterial response after balloon angioplasty: the natural history of remodeling. Cardiovasc Res. 1998;39:224-232.
20. Zhang HM, Yan YP, Sun GC, et al. Cutaneous blood vessels in scent pigs. Plast Reconstr Surg. 2000;106:1555-1565.
21. Guyuron B, Michelow B, Schmelzer R, et al. Delayed healing of rhytidectomy flap resurfaced with CO2 laser. Plast Reconstr Surg. 1998;101:816-819.
22. Dixit VM, Galvin NJ, O'Rourke KM, et al. Monoclonal antibodies that recognize calcium-dependent structures of human thrombospondin. Characterization and mapping of their epitopes. J Biol Chem. 1986;261:1962-1968.
23. Shahein YE, de Andres DF, Perez de la Lastra JM. Molecular cloning and functional characterization of the pig homologue of integrin-associated protein (IAP/CD47). Immunology. 2002;106:564-576.
24. Annis DS, Murphy-Ullrich JE, Mosher DF. Function-blocking anti-thrombospondin-1 monoclonal antibodies. J Thromb Haemost. 2006;4:459-468.
25. Agah A, Kyriakides TR, Lawler J, et al. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol. 2002;161:831-839.
26. Roth JJ, Buckmire MA, Rolandelli RH, et al. Localization of thrombospondin-1 and its cysteine-serine-valine-threonine-cysteine-glycine receptor in colonic anastomotic healing tissue. Histol Histopathol. 1998;13:967-971.
27. Roth JJ, Sung JJ, Granick MS, et al. Thrombospondin 1 and its specific cysteine-serine-valine-threonine-cysteine-clycine receptor in fetal wounds. Ann Plast Surg. 1999;42:553-563.
28. Saika S, Miyamoto T, Ishida I, et al. Accumulation of thrombospondin-1 in post-operative capsular fibrosis and its down-regulation in lens cells during lens fiber formation. Exp Eye Res. 2004;79:147-156.
29. Phelan MW, Forman LW, Perrine SP, et al. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J Lab Clin Med. 1998;132:519-529.
30. Favier J, Germain S, Emmerich J, et al. Critical overexpression of thrombospondin 1 in chronic leg ischaemia. J Pathol. 2005;207:358-366.
31. Levin LS. The reconstructive ladder. An orthoplastic approach. Orthop Clin North Am. 1993;24:393-409.
32. Raghunathan A, Rapp JH, Littooy F, et al. Postoperative outcomes for patients undergoing elective revascularization for critical limb ischemia and intermittent claudication: a subanalysis of the Coronary Artery Revascularization Prophylaxis (CARP) trial. J Vasc Surg. 2006;43:1175-1182.
33. Ryan T. The ageing of the blood supply and the lymphatic drainage of the skin. Micron. 2004;35:161-171.
34. Harris NR, Rumbaut RE. Age-related responses of the microcirculation to ischemia-reperfusion and inflammation. Pathophysiology. 2001;8:1-10.
35. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295:547-553.
36. Bolz SS, Vogel L, Sollinger D, et al. Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation. 2003;107:3081-3087.
37. Isenberg JS, Ridnour LA, Espey MG, et al. Nitric oxide in wound-healing. Microsurgery. 2005;25:442-451.
38. Knox LK, Stewart AG, Hayward PG, et al. Nitric oxide synthase inhibitors improve skin flap survival in the rat. Microsurgery. 1994;15:708-711.
39. Mullershausen F, Russwurm M, Koesling D, et al. The enhanced NO-induced cGMP response induced by long-term L-NAME treatment is not due to enhanced expression of NO-sensitive guanylyl cyclase. Vascul Pharmacol. 2003;40:161-165.
40. Pandolfi A, Grilli A, Cilli C, et al. Phenotype modulation in cultures of vascular smooth muscle cells from diabetic rats: association with increased nitric oxide synthase expression and superoxide anion generation. J Cell Physiol. 2003;196:378-385.
41. Buchwalow IB, Podzuweit T, Samoilova VE, et al. An in situ evidence for autocrine function of NO in the vasculature. Nitric Oxide. 2004;10:203-212.
42. Hecker M, Cattaruzza M, Wagner AH. Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Gen Pharmacol. 1999;32:9-16.
43. MacNaul KL, Hutchinson NI. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun. 1993;196:1330-1334.
44. Isenberg JS, Jia Y, Fukuyama J, et al. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem. 2007;282:15404-15415.
45. Isenberg JS, Romeo MJ, Yu C, et al. Thrombospondin-1 stimulates platelet aggregation by blocking the anti-thrombotic activity of nitric oxide/cGMP signaling. Blood. 2008;111:613-623.
46. Bostick AC, Stoffregen DE, Johnson TE. Response of lightly and highly pigmented porcine skin (Sus scrofa domestica) to single 3.8-microm laser radiation pulses. J Am Assoc Lab Anim Sci. 2006;45:33-37.
47. Van Dorp AG, Verhoeven MC, Koerten HK, et al. Dermal regeneration in full-thickness wounds in Yucatan miniature pigs using a biodegradable copolymer. Wound Repair Regen. 1998;6:556-568.
48. Russell JA, Conforti ML, Connor NP, et al. Cutaneous tissue flap viability following partial venous obstruction. Plast Reconstr Surg. 2006;117:2259-2266; discussion 2267-2268.
49. Harder Y, Contaldo C, Klenk J, et al. Improved skin flap survival after local heat preconditioning in pigs. J Surg Res. 2004;119:100-105.